Skip to content

Press Releases and Events

PRESS RELEASES AND EVENTS

Events

There are currently no events to display.

Archived Events

There are currently no events to display.

Press Releases

Date Title and Summary View
Toggle Summary Intra-Cellular Therapies Presents Data on its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders. View HTML
Toggle Summary Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia. View HTML
Toggle Summary Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs. View HTML
Toggle Summary Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD). View HTML
Toggle Summary Intra-Cellular Therapies Initiates Phase I Clinical Program for Schizophrenia and Sleep Maintenance Disorders.
ITI-007 - A Novel, First-in-Class Dual 5HT2A Receptor Antagonist/Dopamine Phosphoprotein Modulator (DPPM) for Schizophrenia and ITI-722- A 5HT2A Receptor Antagonist for Sleep Maintenance Disorders
View HTML
Toggle Summary Intra-Cellular Therapies, Inc. Receives Exclusive License for Central Nervous System Compounds from Bristol-Myers Squibb Company. View HTML